First-In-Human Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of G1T28-1 in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Trilaciclib (Primary)
- Indications Cancer; Myelosuppression
- Focus Adverse reactions; First in man
- Sponsors G1 Therapeutics
- 09 Aug 2017 Phase 1 and preclinical data for trilaciclib published in Science Translational Medicine, according to G1 Therapeutics financial report.
- 29 Jun 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.